From: A novel nasal powder formulation of glucagon: toxicology studies in animal models
Day | Group | Dose level of glucagon (mg/day) | Mean (± SE) | ||||
---|---|---|---|---|---|---|---|
AUC0–t (pg min/mL) | AUC0–90 (pg min/mL) | Cmax (pg/mL) | tmax (min) | RA | |||
1 | Low dose | 0.1 | 8095 ± 3266 | 8095 ± 3266 | 390 ± 240 | 10.0 | NC |
High dose | 0.2 | 172,893 ± 72,774 | 172,893 ± 72,774 | 9961 ± 6443 | 10.0 | NC | |
28 | Low dose | 0.1 | 43,036 ± 21,047 | 43,036 ± 21,047 | 988 ± 851 | 60.0 | 5.31 |
High dose | 0.2 | 60,073 ± 20,639 | 60,073 ± 20,639 | 2109 ± 1464 | 20.0 | 0.347 |